Skeptic critique for analysis AD-MASTER-PLAN-GFAP-20260428030756: AD Master Plan preregistration: GFAP
The analysis question is substantive, but the current record does not by itself prove the claim. The main dissent is: GFAP is a state marker more than a specific intervention point, and reactive astrocytes can be protective or harmful.
The debate should reject overclaiming in three forms. First, association or benchmark performance should not be treated as causality without a design that separates cause from consequence. Second, a positive average effect can hide subgroup failure across GFAP, AD, tau, amyloid. Third, an analysis that lacks provenance, environment capture, or preregistered endpoints can produce plausible but non-reproducible conclusions.
A decisive falsifier would be failure of resolve GFAP-positive astrocyte subtypes by spatial transcriptomics and perturb metabolic support pathways in neuron-astrocyte systems to move the predicted proximal endpoint under adequate power and controls. The strongest alternative explanation is that the observed signal is a disease-stage marker, prompt or notebook artifact, or compensatory response rather than an upstream driver.